These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 28155054)

  • 1. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
    Kubo M; Kawai M; Kumamaru H; Miyata H; Tamura K; Yoshida M; Ogo E; Nagahashi M; Asaga S; Kojima Y; Kadoya T; Aogi K; Niikura N; Miyashita M; Iijima K; Hayashi N; Yamamoto Y; Imoto S; Jinno H
    Breast Cancer Res Treat; 2019 Dec; 178(3):647-656. PubMed ID: 31451979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
    Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
    Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
    JAMA Oncol; 2018 Sep; 4(9):1199-1206. PubMed ID: 29852043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
    Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
    Dalenc F; Penault-Llorca F; Cohen M; Houvenaeghel G; Piat JM; Liegeois P; Puyuelo L; Suchaud JP; Zouai M; Lacroix-Triki M; Radosevic-Robin N; Benkanoun C; Attar-Rabia H; Chauvet MP; Gligorov J; Belkacemi Y
    Clin Breast Cancer; 2017 Apr; 17(2):107-116. PubMed ID: 27856201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
    Chumsri S; Li Z; Serie DJ; Mashadi-Hossein A; Colon-Otero G; Song N; Pogue-Geile KL; Gavin PG; Paik S; Moreno-Aspitia A; Perez EA; Thompson EA
    J Clin Oncol; 2019 Dec; 37(35):3425-3435. PubMed ID: 31622131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
    Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy.
    Cao L; Cai G; Xu F; Yang ZZ; Yu XL; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Medicine (Baltimore); 2016 Aug; 95(32):e4230. PubMed ID: 27512838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
    Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?
    Wong FY; Yip CS; Chua ET
    World J Surg; 2012 Feb; 36(2):287-94. PubMed ID: 22105650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
    Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.